Quick Answer
BRAINSTORM CELL THERAPEUTICS INC. reported Net Income of -$10.31 million for fiscal year 2025.
BRAINSTORM CELL THERAPEUTICS INC. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$10.31M | +11.3% |
| 2024 | -$11.62M | +32.4% |
| 2023 | -$17.19M | +29.2% |
| 2022 | -$24.28M | +0.7% |
| 2021 | -$24.46M | +23.1% |
| 2020 | -$31.81M | -36.8% |
| 2019 | -$23.25M | -66.7% |
| 2018 | -$13.95M | -181.7% |
| 2017 | -$4.95M | +0.6% |
| 2016 | -$4.98M | +41.3% |
| 2015 | -$8.49M | +8.2% |
| 2014 | -$9.25M | -88.7% |
| 2013 | -$4.90M | -42.8% |
| 2012 | -$3.43M | +12.5% |
| 2011 | -$3.92M | -62.0% |
| 2010 | -$2.42M | -35.8% |
| 2009 | -$1.78M | +48.7% |
| 2008 | -$3.47M | +44.4% |
| 2007 | -$6.24M | -88.2% |
| 2006 | -$3.32M | +82.4% |
| 2005 | -$18.84M | -25708.2% |
| 2004 | -$73.0K | -55.3% |
| 2003 | -$47.0K | -80.8% |
| 2002 | -$26.0K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.11M | +22.2% | +27.5% |
| June 30, 2025 | -$2.90M | -14.2% | -1.4% |
| March 31, 2025 | -$2.86M | +15.8% | -5.8% |
| September 30, 2024 | -$2.71M | -120.9% | -6.6% |
| June 30, 2024 | -$2.54M | +52.3% | +25.3% |
| March 31, 2024 | -$3.40M | +32.8% | -177.4% |
| September 30, 2023 | -$1.23M | +82.1% | +77.0% |
| June 30, 2023 | -$5.33M | +24.3% | -5.3% |
- BRAINSTORM CELL THERAPEUTICS INC. showed an increase of +11.3% in Net Income compared to the prior fiscal year.
- Over the 2002–2025 period, BRAINSTORM CELL THERAPEUTICS INC.’s net income has declined by 39542.3% (from -$26.0 thousand to -$10.31 million).
- The most recent figure is from BRAINSTORM CELL THERAPEUTICS INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: